- Home
- EVOK vs SNGX Comparison
EVOK vs SNGX Comparison
Compare EVOK & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- SNGX
- Stock Information
- Founded
- EVOK 2007
- SNGX 1987
- Country
- EVOK United States
- SNGX United States
- Employees
- EVOK N/A
- SNGX N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- SNGX Health Care
- Exchange
- EVOK Nasdaq
- SNGX Nasdaq
- Market Cap
- EVOK 6.5M
- SNGX 7.4M
- IPO Year
- EVOK 2013
- SNGX 1987
- Fundamental
- Price
- EVOK $4.47
- SNGX $2.43
- Analyst Decision
- EVOK
- SNGX
- Analyst Count
- EVOK 0
- SNGX 0
- Target Price
- EVOK N/A
- SNGX N/A
- AVG Volume (30 Days)
- EVOK 29.5K
- SNGX 621.9K
- Earning Date
- EVOK 03-13-2025
- SNGX 03-14-2025
- Dividend Yield
- EVOK N/A
- SNGX N/A
- EPS Growth
- EVOK N/A
- SNGX N/A
- EPS
- EVOK N/A
- SNGX N/A
- Revenue
- EVOK $8,617,036.00
- SNGX $364,183.00
- Revenue This Year
- EVOK $97.35
- SNGX N/A
- Revenue Next Year
- EVOK $99.52
- SNGX $76.64
- P/E Ratio
- EVOK N/A
- SNGX N/A
- Revenue Growth
- EVOK 100.35
- SNGX N/A
- 52 Week Low
- EVOK $3.54
- SNGX $1.83
- 52 Week High
- EVOK $12.32
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- EVOK 47.52
- SNGX 35.71
- Support Level
- EVOK $4.30
- SNGX $2.03
- Resistance Level
- EVOK $4.58
- SNGX $2.68
- Average True Range (ATR)
- EVOK 0.26
- SNGX 0.33
- MACD
- EVOK -0.00
- SNGX -0.06
- Stochastic Oscillator
- EVOK 48.22
- SNGX 20.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).